the results of sample size based on PowerTOST [Software]

posted by libaiyi – China, 2018-07-27 07:34 (1771 d 02:45 ago) – Posting: # 19107
Views: 5,920

(edited by libaiyi on 2018-07-27 07:47)


I have a naive question about the results of sample size based on SampleN.TOST, sampleN.NTIDFDA, sampleN.HVNTID etc.

For example,

++++++++ Reference scaled ABE crit. +++++++++
           Sample size estimation
Study design:  2x3x3 (partial replicate)
log-transformed data (multiplicative model)
1e+05 studies for each step simulated.

alpha  = 0.05, target power = 0.8
CVw(T) = 0.3; CVw(R) = 0.3
True ratio = 0.9
ABE limits / PE constraints = 0.8 ... 1.25
FDA regulatory settings
- CVswitch            = 0.3
- regulatory constant = 0.8925742
- pe constraint applied

Sample size search
 n     power
39   0.75781
42   0.78122
45   0.80344

I want to know if the target power is 0.8, the sample size is 45 for each group or for whole study.

The other question,
when we apply power.TOST, the sample size we need to fill in should be number in each group or whole study.

Third question,:-):-):-):-)
I am confused about the relationship between power and period. Are the power calculation method applied in 2*2, 3*3 and 2*4 designs the same?:-D For example, if I have the result like this of the study design as T-S-R, could I use the same method to calculate power separately for T-R and S-R? Should I get two power as the result? And, what about parallel design?


Thanks in advance! :flower:

Complete thread:

UA Flag
 Admin contact
22,616 posts in 4,740 threads, 1,611 registered users;
19 visitors (1 registered, 18 guests [including 10 identified bots]).
Forum time: 10:20 CEST (Europe/Vienna)

Nerds don’t just happen to dress informally.
They do it too consistently.
Consciously or not, they dress informally
as a prophylactic measure against stupidity.    Paul Graham

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz